Integrin alpha M

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Retrieved on: 
星期一, 四月 22, 2024
Brain, Euronext Growth, Pericyte, IDUA, Traffic barrier, Integrin alpha M, HSPC, Mouse, CD4, Myelocyte, CD20, Cell, Intron, DNA, Therapy, Patient, Gene, Society, BBB, DSM-IV codes, Mucopolysaccharidosis, Vaccine

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first data exploring novel TALEN® editing processes in hematopoietic stem and progenitor cells (HSPCs) at the American Society of Gene and Cell Therapy (ASGCT) being held on May 7-11, 2024.

Key Points: 
  • “These two posters showcase the potential and versatility of the TALEN® technology to promote efficient gene insertion in HSPCs.
  • Cellectis has developed a TALEN® mediated promoter-less intron editing technology that enables the expression of a therapeutic transgene exclusively by monocyte derived from edited HSPCs.
  • This novel editing approach is an important addition to the HSPC gene editing toolbox that might unlock new strategies for the treatment of metabolic and neurological diseases.
  • Cellectis has developed and optimized a novel gene editing process, leveraging the TALEN® technology and circular single strand DNA template delivery, enabling highly efficient gene insertion in HSPCs.

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
星期日, 十一月 19, 2023
Temozolomide, Safety, Glioblastoma, Dana–Farber Cancer Institute, GBM, Molecular medicine, Medicine, TMZ, Patient, Tokyo Stock Exchange, Immunohistochemistry, Neoplasm, Integrin alpha M, Harvard Medical School, Survival, CD74, Cleveland Clinic, Society, SNO, CD3, Standard Market Design, Life, Biopsy, Code, Pharmaceutical industry, Neurology

The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

Key Points: 
  • The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
  • MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.
  • MediciNova is grateful to the patients and families for their invaluable participation in our trial.”

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Retrieved on: 
星期二, 十月 24, 2023
Knowledge, Gene editing, ISCB Senior Scientist Award, TC, AAV, Therapy, HBB, SCD, Y RNA, Architecture, Euronext Growth, Genome, Cell, Risk, Gene, Integrin alpha M, Congress, ESGCT, European Society of Gene and Cell Therapy, Red blood cell, Myelocyte, DNA, Vaccine, HSPC

The data will be presented in three posters:

Key Points: 
  • The data will be presented in three posters:
    Presenter: Eduardo Seclen, Senior Scientist & Team Leader, Gene Editing
    Intronic editing enables lineage specific expression of therapeutics relevant for HSPC gene therapy.
  • TALEN®-mediated intron editing of the CD11b locus results in the lineage-specific expression of a reporter transgene in myeloid cells, with negligible expression in HSPC or other cellular subsets in vitro and in vivo.
  • We believe this intron editing approach could be disruptive in HSPC gene therapy and brain delivery of multiple therapeutics.
  • Using a combination of scRNA sequencing and multiple genomic read out methodologies, we demonstrate that the mutant HBB gene can be efficiently corrected in HSPCs by TALEN®-mediated gene editing coupled to non-viral gene delivery (ssODN) with a low risk of generating β-thalassemic RBCs.

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Retrieved on: 
星期一, 九月 11, 2023
PK, Integrin alpha M, PD, Therapy, C5a, Neutrophil, Conference call, Receptor (biochemistry), Biotechnology, Inflammation, COVID-19, Aes, SAD, Cmax, EDT, Plasma, Patient, Hidradenitis suppurativa, MAD, Septic, Downregulation and upregulation, Conference, Fasting, Safety, Disease, Pharmaceutical industry, Cryptocurrency

The main objectives were to assess safety and tolerability of single ascending doses under fasting conditions.

Key Points: 
  • The main objectives were to assess safety and tolerability of single ascending doses under fasting conditions.
  • We look forward to seeing the results from the MAD part of the study and advancing INF904 in development,” commented Renfeng Guo, M.D., Chief Scientific Officer and Founder of InflaRx.
  • Analysis of INF904 PK in subject plasma samples revealed sustained exposure to INF904 with six hours to maximum concentration (tmax).
  • INF904 plasma levels were dose proportional for systemic exposure (AUClast) and nearly dose proportional for maximum concentration (Cmax) over the dose range used in the study.

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

Retrieved on: 
星期一, 二月 20, 2023
Society, Dana–Farber Cancer Institute, Circulatory system, Perk, Tokyo Stock Exchange, Temozolomide, Mothers (Tokyo Stock Exchange), Tissue, Brain mapping, Integrin alpha M, HIV disease progression rates, Immunohistochemistry, Harvard Medical School, Glioblastoma, Society for Brain Mapping and Therapeutics, Professor, Therapy, Biopsy, Cleveland Clinic, CD74, Congress, Molecular medicine, TMZ, Part, CD3, Neoplasm, Code, Principal, Doctor of Philosophy, Medicine, Medical imaging, Neurology

MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.

Key Points: 
  • MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.
  • This tumor analysis study was a collaborative effort between MediciNova, Dr. Patrick Wen (Dana- Farber Cancer Institute), and Dr. Lathia (Cleveland Clinic Foundation).
  • Immunohistochemistry was performed on resected tumor tissue to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74.
  • Recently, we have completed study enrollment with MN-166-GBM-1201 study and look forward to the upcoming data analysis with more tissue samples.”